Stem Cell Therapy for Corneal Blindness (Limbal Stem Cell Deficiency)

What This Article Covers

This article looks at stem cell therapy for limbal stem cell deficiency (LSCD), a cause of corneal blindness — and one of the genuine success stories in the field. A stem-cell-based product called Holoclar is approved in the European Union for LSCD caused by eye burns, backed by real clinical data showing most patients keep a stable, healthier corneal surface a year after treatment. We also explain, clearly, what this therapy can't yet do: no equivalent product is approved by the FDA in the United States, and outcomes vary by cause and severity of the underlying damage.

Limbal stem cell deficiency happens when the limbus — the narrow ring of tissue at the edge of the cornea that houses the eye's own corneal stem cells — is damaged or destroyed. Those stem cells normally renew the clear corneal surface every few days. Without them, the eye can't repair itself: the surface becomes clouded, scarred, or overgrown by neighboring conjunctival tissue, causing pain, light sensitivity, and progressive vision loss that can end in blindness. Common causes include chemical or thermal burns (the most frequent trigger for severe cases), long-term contact lens overuse, autoimmune and inflammatory conditions such as Stevens-Johnson syndrome and mucous membrane pemphigoid, and inherited conditions like congenital aniridia.

How It's Thought to Work

The approach, generally called cultivated limbal epithelial transplantation (CLET), works by giving the eye back a working population of its own stem cells. Surgeons take a tiny biopsy (as little as 1-2 mm²) of healthy limbal tissue from the patient's less-damaged or unaffected eye. In a specialized lab, those cells are expanded over several weeks into a sheet of tissue — described in EU regulatory documents as "ex-vivo expanded autologous human corneal epithelium containing stem cells" — then surgically grafted onto the damaged eye, where the goal is for the transplanted stem cells to take root in the limbus and resume producing healthy corneal surface. Because the cells come from the patient's own body, the risk of immune rejection is much lower than with donor tissue.

What the Evidence Shows

The strongest evidence comes from Holoclar, developed by Chiesi/Holostem, which in 2015 became the first stem-cell-based medicine to receive marketing authorization in the European Union — a genuine milestone for regenerative medicine — and moved to full (non-conditional) authorization in 2024 after continued positive review, per the European Medicines Agency (EMA). It's approved specifically for adults with moderate to severe LSCD caused by ocular burns. In the pivotal case series reviewed by the EMA, 75 of 104 treated patients (72%) had a successful outcome one year after implantation, meaning a stable corneal surface free of defects and with little abnormal blood vessel growth — and many patients also reported less pain and inflammation and improved vision. Side effects reported included eye pain, corneal defects, and eyelid inflammation, mostly manageable. Separately, a 2021 review in Pharmaceutics (MDPI) of the broader field describes cultivated limbal transplantation as capable of restoring a functional corneal surface but stresses that outcomes depend heavily on how much healthy limbal tissue remains and on the underlying disease. In the US, no comparable product has FDA approval, but momentum is building: Chiesi and Holostem received FDA Orphan Drug Designation in 2018 for a related product, GPLSCD01, and a Mass Eye and Ear/Massachusetts General Brigham phase I/II trial of a US-manufactured cultivated stem cell graft (CALEC), published in 2025, reported a success rate above 90% at 12 and 18 months in 14 patients with no serious treatment-related adverse events — an encouraging early result, though it remains investigational and is not yet available at any US hospital.

Who Might Be a Candidate

• Adults with moderate to severe limbal stem cell deficiency confirmed by an ophthalmologist, most typically from chemical or thermal eye burns
• Patients with at least one eye retaining enough healthy limbal tissue to serve as a biopsy source (for the autologous approach used in approved and trial therapies)
• People who have exhausted or are not suited to conventional treatments, such as amniotic membrane grafts or standard corneal transplant, which often fail without a working limbal stem cell supply
• Patients located where an approved product is available — currently the EU for Holoclar — or who qualify for a clinical trial elsewhere, such as ongoing US studies
• Not (yet) an option for most US patients seeking an FDA-approved stem cell product for this condition, since none currently exists

Bottom Line

Corneal blindness from limbal stem cell deficiency is one of the clearest examples of stem cell science translating into an approved, working medicine — Holoclar has genuinely restored functional vision-supporting corneal surfaces for many patients in Europe, and similar US-developed approaches are showing strong early results. At the same time, this is a specialized therapy for a specific set of patients, with real risks, incomplete success in roughly a quarter of treated cases, and no FDA-approved option yet in the United States. Anyone experiencing symptoms of LSCD should be evaluated by a corneal specialist to understand what's realistically available today, and what may become available as ongoing US trials mature.